The therapeutic potential of escitalopram in the treatment of panic disorder

Código QR

The therapeutic potential of escitalopram in the treatment of panic disorder

Mark H Townsend, Erich J ConradDepartment of Psychiatry, Louisiana State University Health Sciences Center New Orleans, New Orleans, Louisiana, USAAbstract: Panic disorder is a chronic and disabling condition that is often accompanied by other psychiatric and medical conditions. The serotonin reupta...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mark H Townsend, Erich J Conrad
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/8e1726ca253f4d98a0d7097f13e84c6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Mazen K Ali, et al.
Publicado: (2011)

Pharmacotherapy of panic disorder
por: Charles B Pull, et al.
Publicado: (2008)

Pharmacological management of panic disorder
por: Carlo Marchesi
Publicado: (2008)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
por: Aoki A, et al.
Publicado: (2014)

Duloxetine in panic disorder with somatic gastric pain
por: Preve M, et al.
Publicado: (2013)

Decreased mean platelet volume in panic disorder
por: Göğçegöz Gül I, et al.
Publicado: (2014)

Differential attentional bias in generalized anxiety disorder and panic disorder
por: Chen J, et al.
Publicado: (2013)

Increased mean platelet volume in patients with panic disorder
por: Kokacya MH, et al.
Publicado: (2015)

Efficacy of atropine combined with paroxetine in vagus nerve excitatory panic disorder
por: Du N, et al.
Publicado: (2015)

Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong JH, et al.
Publicado: (2015)

Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study
por: Dell&#39;Osso B, et al.
Publicado: (2013)

Safety of escitalopram in pregnancy: a case series
por: Bellantuono C, et al.
Publicado: (2013)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton B, et al.
Publicado: (2018)

Lower serum brain-derived neurotrophic factor levels are associated with failure to achieve remission in patients with major depression after escitalopram treatment
por: Lee BH, et al.
Publicado: (2014)

Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
por: Levitan MN, et al.
Publicado: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez E, et al.
Publicado: (2014)

Serotonin syndrome induced by the readministration of escitalopram after a short-term interruption in an elderly woman with depression: a case report
por: Sato Y, et al.
Publicado: (2015)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga J, et al.
Publicado: (2015)

Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress
por: Caldirola D, et al.
Publicado: (2019)

A review of the potential therapeutic role of statins in the treatment of Alzheimer&rsquo;s disease: current research and opinion
por: Mitchell AJ, et al.
Publicado: (2013)

Tailoring therapeutic strategies for treating posttraumatic stress disorder symptom clusters
por: Seth D Norrholm, et al.
Publicado: (2010)

MicroRNA as therapeutic targets for treatment of depression
por: Hansen KF, et al.
Publicado: (2013)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang J, et al.
Publicado: (2018)

Indiplon in the treatment of sleep disorders
por: Alan Lankford
Publicado: (2007)

Lurasidone as a potential therapy for bipolar disorder
por: Woo YS, et al.
Publicado: (2013)

Ziprasidone in the treatment of mania in bipolar disorder
por: Stephen E Nicolson, et al.
Publicado: (2007)

Armodafinil in the treatment of sleep/wake disorders
por: Jonathan RL Schwartz, et al.
Publicado: (2010)

Duloxetine in the treatment of generalized anxiety disorder
por: Trevor R Norman, et al.
Publicado: (2009)

Desvenlafaxine in the treatment of major depressive disorder
por: Maria Teresa C Lourenco1, et al.
Publicado: (2009)

The role of duloxetine in the treatment of anxiety disorders
por: Domenico De Berardis, et al.
Publicado: (2008)

Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders
por: Prasko J, et al.
Publicado: (2016)

Novel glutamatergic drugs for the treatment of mood disorders
por: Murrough JW, et al.
Publicado: (2013)

Treatment of adults with attention-deficit/hyperactivity disorder
por: Dusan Kolar, et al.
Publicado: (2008)

Personality disorders and treatment drop out in the homeless
por: Salavera C, et al.
Publicado: (2013)

Treatment of adults with attention-deficit/hyperactivity disorder
por: Dusan Kolar, et al.
Publicado: (2008)

A review of ramelteon in the treatment of sleep disorders
por: David N Neubauer
Publicado: (2008)

Pregabalin for the treatment of generalized anxiety disorder: an update
por: Baldwin DS, et al.
Publicado: (2013)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: J Craig Nelson, et al.
Publicado: (2008)

Duloxetine for the treatment of generalized anxiety disorder: a review
por: Ahsan Y Khan, et al.
Publicado: (2008)

Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis GA, et al.
Publicado: (2015)